Nature, Published online: 28 February 2024; doi:10.1038/s41586-024-07121-9
A high baseline of intratumoural macrophages and regulatory T cells is associated with better outcomes in patients with non-small cell lung cancer treated with atezolizumab plus tiragolumab, but not with atezolizumab alone.
Source link